David Francisco - 22 Feb 2023 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Chief Financial Officer
Signature
/s/ William R. Kolb, Attorney-in-Fact
Issuer symbol
ORGO
Transactions as of
22 Feb 2023
Transactions value $
$0
Form type
4
Filing time
24 Feb 2023, 16:49:31 UTC
Previous filing
17 Feb 2023
Next filing
20 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Award $0 +243K +490.7% $0.00 292K 22 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Award $0 +288K $0.00 288K 22 Feb 2023 Class A Common Stock 288K $2.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023.
F2 The option becomes exercisable in equal annual installments over four years beginning February 15, 2023.